Peripartum Cardiomyopathy
Overview
Peripartum cardiomyopathy (PPCM) is an idiopathic dilated cardiomyopathy presenting in the final month of pregnancy or within 5 months postpartum (Pearson 2000 Working Group definition) in the absence of prior heart disease and in the absence of any identifiable cause of heart failure. The heart dilates and ejection fraction falls below 45%, causing heart failure symptoms in a previously healthy young woman. PPCM is one of the most important causes of maternal mortality in the modern era.
Despite its severity, PPCM is frequently misdiagnosed as normal pregnancy-related breathlessness. Dyspnea during pregnancy is ubiquitous, but orthopnea (breathlessness when lying flat) is NOT a normal feature of pregnancy; it is a heart-failure warning sign, and an echocardiogram (heart ultrasound) is the test that shows whether the heart muscle is failing. Delays in diagnosis worsen outcomes and increase the risk of irreversible ventricular remodeling, thromboembolic complications, and sudden death.
Incidence varies widely by population: approximately 1:1,000–3,000 live births globally; in Nigeria and Haiti approximately 1:100–1:300; Japan among the lowest reported rates; the United States approximately 1:2,500. Rates appear to be increasing, most likely reflecting improved detection and reporting rather than a true rise in incidence.
Epidemiology and Risk Factors
PPCM does not occur at random — multiple demographic, obstetric, and systemic risk factors have been consistently identified across large registries:
- Older maternal age (>30 years): increasing risk with advancing age at delivery.
- Multiparity (3 or more pregnancies): cumulative cardiovascular demands of repeated pregnancies.
- Twin or multiple gestation: 2–3 times increased risk; markedly elevated hemodynamic demands on the heart.
- Preeclampsia and gestational hypertension: the most consistently identified risk factor; a 2013 meta-analysis of 22 studies (979 women with PPCM) found preeclampsia in 22%, more than four times the 5% average worldwide background rate, and high blood pressure during pregnancy in 37%. Both share a pathophysiology of endothelial dysfunction and anti-angiogenic signaling.
- African American ethnicity: 5–6 times higher incidence than white women in the United States; significantly worse outcomes including lower recovery rates and higher mortality. Both genetic predisposition and socioeconomic barriers to early diagnosis contribute.
- Cocaine or methamphetamine use: direct cardiotoxicity plus intense vasoconstriction compound hemodynamic stress.
- Selenium deficiency: implicated in endemic cases in rural Haiti and parts of sub-Saharan Africa; selenium is essential for glutathione peroxidase activity, which protects myocytes against oxidative stress.
- Malnutrition and poverty: in endemic regions, nutritional deficiencies compound peripartum cardiovascular vulnerability.
- Prior PPCM: 20–30% risk of recurrence with any subsequent pregnancy, especially if left ventricular function never fully normalized after the index episode.
Women with multiple risk factors — particularly African American ethnicity, preeclampsia, and advanced maternal age — carry the highest absolute risk; in them, breathlessness or fluid retention out of proportion to the stage of pregnancy is a recognized reason for an early echocardiogram.
Pathophysiology — Prolactin, Angiogenic Imbalance, and Genetics
PPCM is not simply dilated cardiomyopathy that happens to occur during pregnancy. A specific pathophysiological mechanism distinct from other cardiomyopathies has been identified, centered on the prolactin hypothesis, with overlapping contributions from angiogenic imbalance and genetic susceptibility.
The Prolactin Hypothesis
The prolactin hypothesis was developed primarily by Hilfiker-Kleiner, Sliwa, and Fett and has become the dominant pathophysiological framework for PPCM:
- Oxidative stress in the peripartum heart — generated by the metabolic demands of pregnancy, breastfeeding, sleep deprivation, and hemodynamic overload — upregulates Cathepsin D, a lysosomal protease, within cardiomyocytes.
- Cathepsin D cleaves full-length 23 kDa prolactin into a 16 kDa anti-angiogenic prolactin fragment.
- This 16 kDa fragment exerts direct cardiac toxicity by: (a) inhibiting cardiomyocyte proliferation and survival; (b) inducing cardiomyocyte apoptosis; (c) impairing the cardiac microvasculature through its anti-angiogenic activity, reducing capillary density and producing ischemic myocardial injury; and (d) acting in a paracrine manner to amplify myocardial damage.
- Prolactin is markedly elevated throughout pregnancy and especially during breastfeeding, providing abundant substrate for 16 kDa fragment generation.
- The therapeutic implication is direct: bromocriptine, a dopamine agonist that suppresses prolactin secretion, would be expected to block 16 kDa fragment generation and protect the myocardium.
Angiogenic Imbalance and sFlt-1
The placenta releases anti-angiogenic sFlt-1 (soluble fms-like tyrosine kinase-1), which sequesters vascular endothelial growth factor (VEGF) and impairs cardiac microvasculature. This mechanism is also central to preeclampsia pathophysiology, explaining the strong epidemiological association between PPCM and preeclampsia — the two conditions share a common anti-angiogenic underpinning. A 2012 study by Patten and colleagues (Arany laboratory, Nature) found abnormally high sFLT1 levels in plasma from women with PPCM; in women late in pregnancy, mild heart dysfunction that caused no symptoms tracked with circulating sFLT1 levels, and in mice sFLT1 alone impaired heart function.
Supporting Evidence for the Prolactin Hypothesis
- Knockout of STAT3 (a signal transducer activated downstream of prolactin) in mice produces a spontaneous PPCM-like syndrome, providing mechanistic validation.
- The 2010 South African pilot study (Sliwa and colleagues, 20 women): bromocriptine added to standard therapy produced significantly better LV recovery versus standard therapy alone.
- Case series from South Africa, Haiti, and Germany confirm high recovery rates with bromocriptine even in severe PPCM.
- The German PPCM Registry confirms the real-world benefit of prolactin blockade.
Genetic Basis — TTN and Other Variants
Damaging (truncating) variants in cardiomyopathy genes were found in about 15% of PPCM patients (26 of 172 women in a 2016 study) — a rate similar to the 17% seen in dilated cardiomyopathy; the 2019 European Society of Cardiology position statement puts the genetic contribution at up to 20% — suggesting that PPCM represents a genetically susceptible heart unmasked by the hemodynamic challenge of pregnancy:
- Titin (TTN) truncating variants (TTNtv): the most common genetic finding in PPCM, present in about 10% of cases. TTN encodes the giant sarcomeric protein titin, which functions as a molecular spring within the sarcomere. TTNtv impair sarcomere integrity and reduce myocardial resilience to the volumetric and pressure demands of pregnancy. The same variants are found in familial DCM.
- DSP (desmoplakin), FLNC (filamin C), SCN5A (cardiac sodium channel), LMNA (lamin A/C): other DCM-linked genes identified in PPCM patients.
- MYH7, TNNT2, TNNI3: sarcomere genes; less commonly implicated in PPCM than in hypertrophic cardiomyopathy.
Clinical Implications of Genetic Testing
Genetic testing is now recommended in PPCM by both the European Society of Cardiology and recent American guidelines. Key implications include:
- LMNA mutations: carry a higher risk of dangerous arrhythmias and sudden cardiac death, supporting earlier ICD implantation even if EF partially recovers.
- TTNtv: in a 2016 study of 83 well-characterized women with PPCM, TTN truncating variants were linked to a lower ejection fraction at 1-year follow-up, so they point to a less favorable recovery.
- Family cascade screening: first-degree relatives of a PPCM patient with a pathogenic TTN, LMNA, or DSP variant are candidates for evaluation at a cardiomyopathy genetics clinic, particularly daughters who may face their own PPCM risk in future pregnancies.
Clinical Presentation and Diagnosis
Onset Timing
- Postpartum onset: approximately 45% of cases, occurring within 5 months after delivery with most cases in the first 3 months.
- Antepartum onset (last month of pregnancy): approximately 40%.
- Earlier antepartum presentation (before the last month): approximately 15% — atypical; other diagnoses are actively considered.
Symptoms
Symptoms mirror those of dilated cardiomyopathy and heart failure but arise in a context where many overlap with normal pregnancy:
- Dyspnea on exertion progressing to dyspnea at rest
- Orthopnea and paroxysmal nocturnal dyspnea (PND): the most clinically important symptoms — orthopnea is NOT a normal feature of pregnancy and is a heart-failure warning sign that echocardiography is used to check
- Profound fatigue from reduced cardiac output
- Lower extremity edema — also common in normal pregnancy, contributing to diagnostic delay
- Palpitations from atrial fibrillation, ventricular tachycardia, or frequent premature ventricular contractions
- Right-sided heart failure symptoms: hepatomegaly, jugular venous distension, ascites in biventricular failure
- Thromboembolic events: LV thrombus occurs in 5–17%; pulmonary embolism and stroke are recognized complications due to the combination of severely reduced EF and pregnancy-associated hypercoagulability
Physical Examination
Tachycardia; laterally displaced apical impulse reflecting LV dilation; S3 gallop; mitral regurgitation murmur from annular dilation; bibasilar pulmonary crackles; elevated jugular venous pressure; and pitting edema of the lower extremities and ankles.
Diagnostic Criteria
Diagnosis is clinical, echocardiographic, and exclusionary. All three conditions are required:
- New onset heart failure in the last month of pregnancy or within 5 months postpartum
- No identifiable cause: not valvular, not congenital, not ischemic coronary disease, not previously known cardiomyopathy
- LV systolic dysfunction: EF <45% on echocardiography (often severely reduced to 20–35% at presentation in acute cases)
Echocardiography and Cardiac Imaging
Echocardiogram — First-Line and Essential
Transthoracic echocardiography is the cornerstone of diagnosis and follow-up in PPCM. Key findings include:
- LV EF <45% (often severely reduced, 20–35% in acute presentation)
- LV dilation — may be less prominent than in chronic DCM if the presentation is early and acute
- Four-chamber dilation in severe biventricular failure
- LV thrombus in 5–17% — careful examination of the LV apex is essential at every evaluation
- Mitral and tricuspid regurgitation from annular dilation
- Pulmonary artery pressure elevation in biventricular failure
LV EF at presentation and at 6 months post-diagnosis is the single most important prognostic marker in PPCM.
Cardiac Magnetic Resonance Imaging
Cardiac magnetic resonance imaging (MRI) is indicated when echocardiographic windows are suboptimal or the diagnosis is uncertain:
- Provides more accurate EF quantification than echocardiography
- Late gadolinium enhancement (LGE) patterns:
- Mid-wall enhancement: idiopathic DCM / PPCM pattern (myocardial fibrosis)
- Subepicardial enhancement: myocarditis pattern (distinguishes from viral myocarditis)
- Subendocardial or transmural enhancement: ischemic pattern (prompts coronary evaluation)
- Safe in pregnancy; gadolinium contrast is generally not given before delivery unless essential, and is used at the lowest dose after delivery when breastfeeding
Biomarkers
BNP and NT-proBNP are markedly elevated in PPCM, correlating with disease severity and falling with effective treatment. Serial measurements are valuable to track therapeutic response. Troponin elevation reflects myocardial injury and often correlates with LGE extent on magnetic resonance imaging. C-reactive protein (CRP) may reflect the inflammatory component of PPCM pathophysiology.
Coronary Assessment
Spontaneous coronary artery dissection (SCAD) is a peripartum-specific cause of myocardial infarction that can mimic PPCM in a young woman presenting with chest pain and heart failure. SCAD is excluded with computed tomography (CT) coronary angiography or invasive coronary angiography, and is usually treated conservatively (PCI worsens dissection propagation in most cases). Standard coronary artery disease is uncommon at this age but possible in the setting of metabolic syndrome or severe preeclampsia-related vascular injury.
Holter Monitoring
Arrhythmias — atrial fibrillation, nonsustained ventricular tachycardia, and frequent PVCs — are common in PPCM. Holter monitoring is part of ICD decision-making and is standard in patients with palpitations or fainting (syncope).
Standard Heart Failure Treatment (Antepartum)
During pregnancy, medicines that harm the unborn baby (teratogenic medicines) are not used. Management focuses on pregnancy-safe agents that reduce hemodynamic burden and prevent complications:
Beta-Blockers (First-Line Antepartum)
- Carvedilol (often chosen): combined alpha + beta blockade provides antiadrenergic and antioxidant properties particularly relevant to PPCM pathophysiology; it is usually started at 3.125 mg twice daily and increased step by step
- Metoprolol succinate (beta-1 selective; well-studied in pregnancy): acceptable alternative
- Atenolol: associated with fetal intrauterine growth restriction, so it is generally not used
- Treatment usually aims for a resting heart rate below 80 beats per minute, with slow dose increases
Diuretics
- Furosemide (loop diuretic): intravenous (IV) for acute decompensated heart failure; oral for maintenance congestion management
- Over-drying (hypovolemia) is a concern — fetal placental circulation depends on adequate maternal intravascular volume
- Before delivery, the lowest effective diuretic dose is generally used rather than high doses
Hydralazine + Nitrates (Afterload Reduction)
- Hydralazine (direct arteriolar vasodilator) + isosorbide dinitrate (venodilator, reduces preload) substitute for angiotensin-converting enzyme inhibitors (ACE inhibitors) during pregnancy
- Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers (ARBs) are absolutely contraindicated in pregnancy — they cause fetal renal agenesis, oligohydramnios, and skull hypoplasia in the second and third trimesters; a single course of angiotensin-converting enzyme inhibitor (ACE inhibitor)/angiotensin receptor blocker (ARB) during pregnancy can cause lethal fetal renal dysgenesis
- The hydralazine + nitrate combination is less potent than angiotensin-converting enzyme inhibitor (ACEi)/angiotensin receptor blocker but is the safest available afterload reduction strategy
Digoxin
Safe in pregnancy. Provides modest positive inotropy and rate control in atrial fibrillation. Limited contemporary use in sinus rhythm given availability of superior agents postpartum, but useful for refractory heart failure or rate control antepartum.
Anticoagulation (Antepartum)
- Low molecular weight heparin (LMWH) — enoxaparin: subcutaneous, does not cross the placenta, safe for the fetus
- Therapeutic anticoagulation is recommended when EF <30% or LV thrombus is identified — the combination of severely reduced EF and pregnancy-associated hypercoagulability creates extreme thromboembolism risk
- Warfarin is generally not used in the first trimester (warfarin embryopathy) or near delivery (maternal and fetal hemorrhage risk); when it is used in the second trimester (e.g., mechanical heart valve), it carries a recognized fetal risk
Delivery Planning
Vaginal delivery is generally preferred in stable PPCM — cardiac output perturbations with vaginal delivery are more predictable than with cesarean section under general anesthesia. Epidural analgesia reduces pain-related catecholamine surges and is beneficial in cardiac patients. Assisted delivery (forceps or vacuum) is planned when prolonged pushing would strain the heart. Oxytocin is given as a slow infusion, not a bolus; ergometrine is contraindicated due to severe vasoconstriction. Hemodynamic monitoring with arterial line — and pulmonary artery catheter in very severe cases — guides real-time management.
Standard Heart Failure Treatment (Postpartum)
After delivery, the full guideline-directed medical therapy (GDMT) arsenal for heart failure with reduced ejection fraction (HFrEF) becomes available. The goal is maximal medical therapy to maximize the probability of LV recovery:
ACE Inhibitors and Angiotensin Receptor Blockers
Enalapril or lisinopril are the backbone of HFrEF therapy. Low doses of enalapril during breastfeeding appear safe (minimal milk transfer). Doses are raised toward target as tolerated, with creatinine and potassium checked closely.
Sacubitril/Valsartan (ARNi)
The angiotensin receptor-neprilysin inhibitor (ARNi) sacubitril/valsartan is superior to angiotensin-converting enzyme inhibitor alone for reducing HFrEF mortality (PARADIGM-HF trial). Because sacubitril/valsartan is teratogenic, it is started only after delivery, usually after breastfeeding has ended or after the risks and benefits have been weighed with the patient. It replaces the angiotensin-converting enzyme inhibitor or angiotensin receptor blocker when added to improve EF.
Sodium-Glucose Cotransporter-2 Inhibitors
Dapagliflozin and empagliflozin carry Class 1A recommendation in HFrEF GDMT based on DAPA-HF and EMPEROR-Reduced trials. Safety during breastfeeding is unknown; they are excreted in breast milk in animal models. Using sodium-glucose cotransporter-2 (SGLT2) inhibitors versus continuing breastfeeding is a trade-off weighed with the patient.
Mineralocorticoid Receptor Antagonists (MRA)
Spironolactone or eplerenone reduce HFrEF mortality and are part of complete GDMT. Spironolactone has weak anti-androgenic effects and is generally not used during breastfeeding due to theoretical concerns for breastfed male infants; it is usually started after breastfeeding ends.
Beta-Blockers (Continued)
Carvedilol or metoprolol succinate started before delivery is continued and raised toward guideline target doses over weeks to months as blood pressure and heart rate allow. Doses are not raised rapidly during active decompensation.
Anticoagulation (Postpartum)
After delivery, LMWH is commonly switched to warfarin (target international normalized ratio (INR) 2–3) if EF remains below 30% or LV thrombus persists. Anticoagulation can be discontinued when EF has recovered to above 40–45% and thrombus has resolved. Direct oral anticoagulants (DOACs) are not recommended during breastfeeding due to inadequate safety data.
Bromocriptine — The Prolactin Hypothesis
Bromocriptine is a dopamine D2 receptor agonist that suppresses prolactin secretion from the anterior pituitary. By blocking prolactin, bromocriptine prevents the generation of the cardiotoxic 16 kDa prolactin fragment by Cathepsin D, protecting the myocardium from prolactin-mediated anti-angiogenic and pro-apoptotic injury.
The South African Pilot Study (Sliwa et al., Circulation 2010)
This single-centre, open-label, randomized proof-of-concept pilot study enrolled 20 South African women with newly diagnosed severe PPCM: 10 received standard heart failure therapy and 10 received standard therapy plus bromocriptine for 8 weeks. At 6 months, ejection fraction in the bromocriptine group had risen from 27% to 58%, against 27% to 36% with standard care (a significant difference). One woman died in the bromocriptine group and four in the standard-care group, and a poor outcome (death, severe heart-failure symptoms or an ejection fraction below 35% at 6 months) occurred in 1 of 10 (10%) versus 8 of 10 (80%). This was the first prospective evidence for bromocriptine as a PPCM-specific treatment; the authors wrote that the number of patients was small and the results cannot be considered definitive. Critics note the small sample size and that the South African population may not fully generalize to other settings.
Subsequent Evidence
- The German PPCM Registry confirmed that bromocriptine use is associated with significantly better LV recovery in real-world clinical practice.
- A 2017 multicentre randomized study in Germany (Hilfiker-Kleiner and colleagues, European Heart Journal) gave 63 women with an ejection fraction of 35% or less either a 1-week course (2.5 mg daily for 7 days) or an 8-week course (5 mg a day for 2 weeks, then 2.5 mg a day for 6 weeks) on top of standard heart failure therapy. Ejection fraction rose by 21 points with the 1-week course and 24 points with the 8-week course, with no significant difference; full recovery (ejection fraction 50% or more) was seen in 52% and 68%, which the authors described as a trend favouring the 8-week course. No woman in the study needed a heart transplant or assist device, and none died.
- In the European Society of Cardiology EORP registry (552 women; an observational, non-randomized analysis), a poor outcome at 6 months (death, hospital readmission or ejection fraction below 35%) occurred in 22% of women given bromocriptine with standard care versus 33% with standard care alone (weighted odds ratio 0.47); blood-clot events were similar (6.0% vs 5.6%).
- A 2025 meta-analysis of 12 studies (2 randomized, 10 observational; 1,765 patients) found that bromocriptine with standard care raised ejection fraction by about 10 percentage points (mean difference 9.98%), but found no significant difference in major cardiac events, death or heart-failure readmission; the authors wrote that larger randomized trials are needed.
- The North American REBIRTH trial (funded by the US National Heart, Lung, and Blood Institute; NCT05180773) is enrolling 200 women within 5 months of delivery with an ejection fraction of 40% or less to compare bromocriptine with placebo on top of standard therapy, plus an observational group of 50 women excluded from randomization because they are breastfeeding; primary results are expected in 2027.
- Data from Nigeria, Haiti, and Germany collectively support prolactin blockade as a meaningful PPCM-specific treatment.
- The 2019 ESC PPCM Position Statement issued a Class IIa, Level B recommendation for bromocriptine.
Practical Use
- Dosing: the longer course in the 2017 trial was 5 mg a day (2.5 mg twice daily) for 2 weeks, then 2.5 mg once daily for 6 weeks; the shorter course was 2.5 mg a day for 7 days
- Anticoagulation with bromocriptine: bromocriptine has been linked to blood clots through uncertain mechanisms, and LMWH thromboprophylaxis is routinely given alongside it
- Suppression of breastfeeding: bromocriptine inhibits lactation, so choosing bromocriptine means stopping breastfeeding (mothers in the 2010 pilot study could not breastfeed). This is a significant and personal decision for the mother
- Use is not yet universal — some centers reserve bromocriptine for severe PPCM (EF <25%) or rapid deterioration; others treat all PPCM; no single standard of care has been established outside of European guidelines
Advanced Therapies and Device Management
Wearable Cardioverter-Defibrillator
Many PPCM patients present with an EF below 35% — the standard threshold for permanent ICD implantation. However, PPCM has a high recovery rate (in the North American IPAC study, 72% of women reached an EF of 50% or more by 1 year). Implanting a permanent ICD in the acute phase is premature and exposes patients who will recover to an unnecessary device. A wearable cardioverter-defibrillator bridges this gap: it provides continuous protection against sudden cardiac death for 3–6 months while recovery is awaited. If EF has not recovered above 35% at 6 months, a permanent ICD is then implanted. This strategy uniquely distinguishes PPCM management from other cardiomyopathy contexts where ICD implantation typically follows immediately upon meeting criteria.
Cardiac Resynchronization Therapy (CRT)
If QRS prolongation (left bundle branch block morphology, QRS duration above 150 ms) persists at 3–6 months in the setting of EF below 35%, cardiac resynchronization therapy with defibrillation capability (CRT-D) is indicated. CRT improves LV mechanical synchrony and can augment EF recovery in PPCM just as in other HFrEF with LBBB.
Left Ventricular Assist Device (LVAD)
LVAD implantation is indicated for cardiogenic shock or rapidly deteriorating PPCM failing maximal medical therapy. PPCM has a notably higher bridge-to-recovery rate compared to other DCM causes, and some patients can successfully undergo LVAD explantation after sufficient cardiac recovery. For patients without recovery, LVAD serves as a bridge to cardiac transplantation.
Cardiac Transplantation
Cardiac transplantation is required in 1–5% of PPCM patients who do not recover LV function despite LVAD support and maximal medical therapy after 6–12 months. Post-transplant outcomes in PPCM are comparable to other DCM etiologies.
Endomyocardial Biopsy
Endomyocardial biopsy is rarely needed but is considered when the diagnosis is uncertain — specifically to exclude giant cell myocarditis, which requires immunosuppressive therapy and has a far worse prognosis than PPCM if untreated. Giant cell myocarditis can present identically to PPCM in the peripartum period.
Acute Decompensated PPCM
Intensive care unit-level management for cardiogenic shock includes vasopressors (norepinephrine plus vasopressin for refractory hypotension; epinephrine is generally not used because it has been linked with higher cardiogenic shock mortality), inodilators (dobutamine for low-output state), intra-aortic balloon pump (IABP), percutaneous ventricular assist devices (microaxial pumps), and venoarterial extracorporeal membrane oxygenation (VA-ECMO) for the most refractory cases as a bridge to LVAD or transplantation.
Subsequent Pregnancy Counseling
Counseling women with a history of PPCM about future pregnancies is one of the most critical and emotionally complex conversations in cardiovascular medicine. The risk of recurrence is real regardless of apparent recovery, and the stakes are high.
Risk Stratification
- Prior PPCM with current normal EF (EF ≥55%): recurrence risk approximately 20%; some patients tolerate a subsequent pregnancy without recurrence; pregnancies are usually managed with preconception counseling, high-risk obstetrics co-management, and cardiology oversight throughout
- Prior PPCM with persistent reduced EF (<55%): subsequent pregnancy is high risk and is generally discouraged; recurrence risk up to 50% with LV decompensation; risk of maternal death is significant; both the 2019 ESC Position Statement and American Heart Association (AHA) guidelines recommend advising against further pregnancy in this setting
- When a woman goes ahead with a pregnancy despite counseling: high-risk obstetric and cardiology co-management throughout pregnancy is standard, with early and frequent echocardiographic monitoring beginning in the first trimester
Two follow-up studies report outcomes of later pregnancies. In a 2001 US study of 44 women with 60 later pregnancies, heart-failure symptoms occurred in 21% of women whose heart function had returned to normal before the next pregnancy and in 44% of women with persistent dysfunction; deaths were 0% and 19%. A 2022 Israeli series of 45 women with 59 later full-term births (most with a recovered ejection fraction, average 57.7%) found only a slight fall in ejection fraction, mostly in the third trimester, relapse in 1 woman whose ejection fraction had been 55% or more and in 3 of the women whose ejection fraction had been below 55%, and no maternal deaths.
Breastfeeding and PPCM
Elevated prolactin during breastfeeding theoretically sustains the generation of the cardiotoxic 16 kDa prolactin fragment. Bromocriptine and breastfeeding do not go together — bromocriptine suppresses lactation as part of its mechanism. If bromocriptine is not used, breastfeeding may continue; the theoretical cardiac risk is part of that decision and the clinical course is monitored closely. The decision is individualized based on the patient's values and the clinical trajectory of LV recovery.
Genetic Counseling
Women with PPCM who carry a pathogenic variant — particularly TTN, LMNA, or DSP — are candidates for formal counseling at a cardiomyopathy genetics clinic. Daughters of PPCM patients with TTN truncating variants face elevated PPCM risk in their own future pregnancies, which matters before they plan families.
Prognosis
Recovery Rates
- Recovery (IPAC study, 100 North American women): average EF rose from 35% at entry to 51% at 6 months and 53% at 12 months; by 1 year, 72% had an EF of 50% or more
- Partial recovery (EF improves but remains below 50%): the remaining women in IPAC who neither reached 50% nor had a major event
- Major events or persistent severe cardiomyopathy (EF below 35%) by 1 year: 13% in IPAC
- Mortality: 3–5% in the first year in high-resource settings; 15–30% in sub-Saharan Africa where diagnosis is delayed and advanced supportive care is unavailable
Predictors of Poor Prognosis
- African American ethnicity: 5–6 times worse outcomes versus white women in United States cohorts
- Low EF at presentation (<30%): one of the strongest predictors of incomplete recovery; in IPAC, no woman with both a starting EF below 30% and a left ventricular end-diastolic diameter of 6.0 cm or more recovered by 1 year, while 91% of those with an EF of 30% or more and a diameter below 6.0 cm recovered. Black race and presentation more than 6 weeks after delivery were also linked to a lower EF at 12 months
- EF remaining below 30% at 6 months: unlikely to recover without advanced device therapy or transplantation
- Concomitant preeclampsia: associated with worse outcomes in some cohorts, though others report that preeclampsia-associated PPCM recovers more completely — data remain mixed
- LMNA mutation: increased arrhythmic sudden cardiac death risk requiring early ICD even after partial EF recovery
- Twin pregnancy: tends to produce more severe initial presentation due to amplified hemodynamic demands
Long-Term Follow-Up
Echocardiography at 6 months is the critical decision point for ICD implantation, transplant listing, and determination of LVAD candidacy. Even after apparent full recovery, annual echocardiography for at least 5 years is recommended because late deterioration of LV function has been documented. Cardiology follow-up typically continues for life, with family planning discussions integrated into every cardiology visit. The 6-month echo is also the appropriate time to re-evaluate genetic testing results and their implications for the patient's care plan.
Key Research Papers
- Sliwa K, Fett J, Elkayam U. "Peripartum cardiomyopathy." Lancet. 2006;368(9536):687–693. — PubMed PMID: 16920474
- Pearson GD, Veille JC, Rahimtoola S, et al. "Peripartum cardiomyopathy: National Heart, Lung, and Blood Institute and Office of Rare Diseases workshop recommendations and review." JAMA. 2000;283(9):1183–1188. — PubMed PMID: 10703781
- Sliwa K, Blauwet L, Tibazarwa K, et al. "Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy: a proof-of-concept pilot study." Circulation. 2010;121(13):1465–1473. — PubMed PMID: 20308616
- Hilfiker-Kleiner D, Kaminski K, Podewski E, et al. "A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy." Cell. 2007;128(3):589–600. — PubMed PMID: 17289576
- McNamara DM, Elkayam U, Alharethi R, et al. "Clinical outcomes for peripartum cardiomyopathy in North America: results of the IPAC Study (Investigations of Pregnancy-Associated Cardiomyopathy)." J Am Coll Cardiol. 2015;66(8):905–914. — PubMed PMID: 26293760
- Ware JS, Li J, Mazaika E, et al. "Shared genetic predisposition in peripartum and dilated cardiomyopathies." N Engl J Med. 2016;374(3):233–241. — PubMed PMID: 26735901
- Hibbard JU, Lindheimer M, Lang RM. "A modified definition for peripartum cardiomyopathy and prognosis based on echocardiography." Obstet Gynecol. 1999;94(2):311–316. — PubMed PMID: 10432149
- Bauersachs J, König T, van der Meer P, et al. "Pathophysiology, diagnosis and management of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy." Eur J Heart Fail. 2019;21(7):827–843. — PubMed PMID: 31243866
- Honigberg MC, Givertz MM. "Peripartum cardiomyopathy." BMJ. 2019;364:k5287. — PubMed PMID: 30700415
- van Spaendonck-Zwarts KY, van Tintelen JP, van Veldhuisen DJ, et al. "Peripartum cardiomyopathy as a part of familial dilated cardiomyopathy." Circulation. 2010;121(20):2169–2175. — PubMed PMID: 20458010
- Arany Z, Elkayam U. "Peripartum cardiomyopathy." Circulation. 2016;133(14):1397–1409. — PubMed PMID: 27045128
- Sliwa K, Petrie MC, van der Meer P, et al. "Clinical characteristics of patients from the worldwide registry on peripartum cardiomyopathy (PPCM): EURObservational Research Programme in conjunction with the Heart Failure Association of the ESC Study Group on PPCM." Eur J Heart Fail. 2017;19(9):1131–1141. — PubMed PMID: 28271625
- Hilfiker-Kleiner D, Haghikia A, Berliner D, et al. "Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre randomized study." Eur Heart J. 2017;38(35):2671–2679. — PubMed PMID: 28934837
- Patten IS, Rana S, Shahul S, et al. "Cardiac angiogenic imbalance leads to peripartum cardiomyopathy." Nature. 2012;485(7398):333–338. — PubMed PMID: 22596155
- Bello N, Rendon ISH, Arany Z. "The relationship between pre-eclampsia and peripartum cardiomyopathy: a systematic review and meta-analysis." J Am Coll Cardiol. 2013;62(18):1715–1723. — PubMed PMID: 24013055
- van der Meer P, van Essen BJ, Viljoen C, et al. "Bromocriptine treatment and outcomes in peripartum cardiomyopathy: the EORP PPCM registry." Eur Heart J. 2025;46(11):1017–1027. — PubMed PMID: 39221911
- Adamu UG, Mojela K, Karaye KM, Tsabedze N. "Bromocriptine in peripartum cardiomyopathy: a meta-analysis with trial sequential analysis." ESC Heart Fail. 2025;12(6):4041–4054. — PubMed PMID: 41213878
- Wang T, Ibarra AJ, Simpson D, et al. "Bromocriptine for myocardial recovery in peripartum cardiomyopathy: design and rationale of the REBIRTH trial." JACC Heart Fail. 2026:103376. — PubMed PMID: 42911149
- Elkayam U, Tummala PP, Rao K, et al. "Maternal and fetal outcomes of subsequent pregnancies in women with peripartum cardiomyopathy." N Engl J Med. 2001;344(21):1567–1571. — PubMed PMID: 11372007
- Goland S, George J, Elkayam U, et al. "Contemporary outcome of subsequent pregnancies in patients with previous peripartum cardiomyopathy." ESC Heart Fail. 2022;9(6):4262–4270. — PubMed PMID: 36128657